Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib.

Strickley JD, Spalding AC, Haeberle MT, Brown T, Stevens DA, Jung J.

Exp Hematol Oncol. 2018 Aug 28;7:20. doi: 10.1186/s40164-018-0111-z. eCollection 2018.

2.

Frameless image-guided radiosurgery for trigeminal neuralgia.

Shields LBE, Shanks TS, Shearer AJ, Shelton LA, Shelton BJ, Howe J, Coons JM, Plato B, Spalding AC.

Surg Neurol Int. 2017 May 26;8:87. doi: 10.4103/2152-7806.207119. eCollection 2017.

3.

Practical considerations of linear accelerator-based frameless extracranial radiosurgery for treatment of occipital neuralgia for nonsurgical candidates.

Denton TR, Shields LBE, Howe JN, Shanks TS, Spalding AC.

J Appl Clin Med Phys. 2017 Jul;18(4):123-132. doi: 10.1002/acm2.12105. Epub 2017 May 18.

4.

Neoadjuvant chemotherapy for atypical teratoid rhabdoid tumors: case report.

Thatikunta M, Mutchnick I, Elster J, Thompson MP, Huang MA, Spalding AC, Moriarty T.

J Neurosurg Pediatr. 2017 May;19(5):546-552. doi: 10.3171/2016.12.PEDS16427. Epub 2017 Mar 10.

PMID:
28291373
5.

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, Bourne TD, LaRocca R, Spalding AC.

Radiat Oncol. 2015 Oct 31;10:222. doi: 10.1186/s13014-015-0527-0.

6.

Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.

Rogers CL, Perry A, Pugh S, Vogelbaum MA, Brachman D, McMillan W, Jenrette J, Barani I, Shrieve D, Sloan A, Bovi J, Kwok Y, Burri SH, Chao ST, Spalding AC, Anscher MS, Bloom B, Mehta M.

Neuro Oncol. 2016 Apr;18(4):565-74. doi: 10.1093/neuonc/nov247. Epub 2015 Oct 22.

7.

Heterogeneity correction for intensity-modulated frameless SRS in pituitary and cavernous sinus tumors: a retrospective study.

Shields LB, Bond C, Odom A, Sun DA, Spalding AC.

Radiat Oncol. 2015 Sep 17;10:193. doi: 10.1186/s13014-015-0500-y.

8.

Quantifying isocenter measurements to establish clinically meaningful thresholds.

Denton TR, Shields LB, Howe JN, Spalding AC.

J Appl Clin Med Phys. 2015 Mar 8;16(2):5183. doi: 10.1120/jacmp.v16i2.5183.

9.

Guidelines for treatment naming in radiation oncology.

Denton TR, Shields LB, Hahl M, Maudlin C, Bassett M, Spalding AC.

J Appl Clin Med Phys. 2015 Nov 7;17(2):123-138. doi: 10.1120/jacmp.v17i2.5953.

10.

Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy.

Zhang Q, Bhojani MS, Ben-Josef E, Spalding AC, Kuick R, Sun Y, Morgan MA.

J Carcinog Mutagen. 2013 Aug 16;4(3):147.

11.

Improvement of therapeutic index for brain tumors with daily image guidance.

Shields LB, Coons JM, Dedich C, Ragains M, Scalf K, Vitaz TW, Spalding AC.

Radiat Oncol. 2013 Dec 2;8:283. doi: 10.1186/1748-717X-8-283.

12.

The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.

Spalding AC, Hawkins DS, Donaldson SS, Anderson JR, Lyden E, Laurie F, Wolden SL, Arndt CA, Michalski JM.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):512-6. doi: 10.1016/j.ijrobp.2013.07.003.

13.

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.

Shields LB, Kadner R, Vitaz TW, Spalding AC.

Radiat Oncol. 2013 Apr 25;8:101. doi: 10.1186/1748-717X-8-101.

14.

Tumor histology and location predict deep nuclei toxicity: Implications for late effects from focal brain irradiation.

Plaga A, Shields LB, Sun DA, Vitaz TW, Spalding AC.

Med Dosim. 2012 Autumn;37(3):276-9. doi: 10.1016/j.meddos.2011.10.002. Epub 2011 Dec 19.

PMID:
22189027
15.

Multimodality treatment of a ruptured grade IV posterior fossa arteriovenous malformation in a patient pregnant with twins: case report.

Dashti SR, Spalding AC, Yao TL.

J Neurointerv Surg. 2012 Sep;4(5):e21. doi: 10.1136/neurintsurg-2011-010059. Epub 2011 Aug 11.

PMID:
21990516
16.

Role of α(5)β(1) Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer Cells.

Yao H, Zeng ZZ, Fay KS, Veine DM, Staszewski ED, Morgan M, Wilder-Romans K, Williams TM, Spalding AC, Ben-Josef E, Livant DL.

Transl Oncol. 2011 Oct;4(5):282-92. Epub 2011 Oct 1.

17.

Ablation of breast cancer stem cells with radiation.

Zielske SP, Spalding AC, Wicha MS, Lawrence TS.

Transl Oncol. 2011 Aug;4(4):227-33. Epub 2011 Aug 1.

18.

Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation.

Zeitlin BD, Spalding AC, Campos MS, Ashimori N, Dong Z, Wang S, Lawrence TS, Nör JE.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):879-87. doi: 10.1016/j.ijrobp.2010.04.024. Epub 2010 Aug 1.

20.

Loss of tumor-initiating cell activity in cyclophosphamide-treated breast xenografts.

Zielske SP, Spalding AC, Lawrence TS.

Transl Oncol. 2010 Jun 1;3(3):149-52.

21.

GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer.

Watson RL, Spalding AC, Zielske SP, Morgan M, Kim AC, Bommer GT, Eldar-Finkelman H, Giordano T, Fearon ER, Hammer GD, Lawrence TS, Ben-Josef E.

Neoplasia. 2010 May;12(5):357-65.

22.

TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis.

Ashimori N, Zeitlin BD, Zhang Z, Warner K, Turkienicz IM, Spalding AC, Teknos TN, Wang S, Nör JE.

Mol Cancer Ther. 2009 Apr;8(4):893-903. doi: 10.1158/1535-7163.MCT-08-1078.

23.

alpha(5)beta(1) Integrin Ligand PHSRN Induces Invasion and alpha(5) mRNA in Endothelial Cells to Stimulate Angiogenesis.

Zeng ZZ, Yao H, Staszewski ED, Rockwood KF, Markwart SM, Fay KS, Spalding AC, Livant DL.

Transl Oncol. 2009 Mar;2(1):8-20.

24.

Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.

Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA.

Clin Cancer Res. 2009 Jan 15;15(2):589-96. doi: 10.1158/1078-0432.CCR-08-1019.

25.

Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.

Spalding AC, Zeitlin BD, Wilder-Romans K, Davis ME, Nor JE, Lawrence TS, Ben-Josef E.

Transl Oncol. 2008 Dec;1(4):195-201.

26.

Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD.

J Clin Endocrinol Metab. 2009 Jan;94(1):204-12. doi: 10.1210/jc.2008-1456. Epub 2008 Oct 14.

27.

Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling.

Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG, Spalding AC, Nör JE.

Neoplasia. 2008 Feb;10(2):131-9.

28.

Radiation therapy reduces local failure and improves overall survival in sPNET.

Spalding AC, Hamstra DA.

Pediatr Blood Cancer. 2008 Jul;51(1):148; author reply 149-50. doi: 10.1002/pbc.21513. No abstract available.

29.

Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.

Spalding AC, Watson R, Davis ME, Kim AC, Lawrence TS, Ben-Josef E.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6827-33.

30.

Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation.

Spalding AC, Daignault S, Sandler HM, Shah RB, Pan CC, Ray ME.

Urology. 2007 May;69(5):936-40.

PMID:
17482938
31.

Using ErbB2-negative status to direct therapy in locally advanced breast cancer.

Spalding AC, Contessa JN.

Cancer Biol Ther. 2007 Mar;6(3):463-4. Epub 2007 Mar 20. No abstract available.

PMID:
17471028
32.

Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions.

Spalding AC, Jee KW, Vineberg K, Jablonowski M, Fraass BA, Pan CC, Lawrence TS, Haken RK, Ben-Josef E.

Med Phys. 2007 Feb;34(2):521-9.

33.

New and emerging radiosensitizers and radioprotectors.

Spalding AC, Lawrence TS.

Cancer Invest. 2006 Jun-Jul;24(4):444-56. Review.

PMID:
16777698
34.

TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells.

Spalding AC, Jotte RM, Scheinman RI, Geraci MW, Clarke P, Tyler KL, Johnson GL.

Oncogene. 2002 Jan 10;21(2):260-71.

35.

Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection.

Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL.

Oncogene. 2001 Oct 18;20(47):6910-9.

36.

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL.

Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL.

Mol Cell Biol. 2000 Jan;20(1):205-12.

Supplemental Content

Loading ...
Support Center